| Literature DB >> 30740053 |
Johan Georg Visser1, Anton Du Preez Van Staden1, Carine Smith1.
Abstract
With the effectiveness of therapeutic agents ever decreasing and the increased incidence of multi-drug resistant pathogens, there is a clear need for administration of more potent, potentially more toxic, drugs. Alternatively, biopharmaceuticals may hold potential but require specialized protection from premature in vivo degradation. Thus, a paralleled need for specialized drug delivery systems has arisen. Although cell-mediated drug delivery is not a completely novel concept, the few applications described to date are not yet ready for in vivo application, for various reasons such as drug-induced carrier cell death, limited control over the site and timing of drug release and/or drug degradation by the host immune system. Here, we present our hypothesis for a new drug delivery system, which aims to negate these limitations. We propose transport of nanoparticle-encapsulated drugs inside autologous macrophages polarized to M1 phenotype for high mobility and treated to induce transient phagosome maturation arrest. In addition, we propose a significant shift of existing paradigms in the study of host-microbe interactions, in order to study microbial host immune evasion and dissemination patterns for their therapeutic utilization in the context of drug delivery. We describe a system in which microbial strategies may be adopted to facilitate absolute control over drug delivery, and without sacrificing the host carrier cells. We provide a comprehensive summary of the lessons we can learn from microbes in the context of drug delivery and discuss their feasibility for in vivo therapeutic application. We then describe our proposed "synthetic microbe drug delivery system" in detail. In our opinion, this multidisciplinary approach may hold the solution to effective, controlled drug delivery.Entities:
Keywords: biopharmaceutical; cell-mediated delivery; expulsion; intracellular pathogen; nano-medicine; phagocytosis; polymer; synthetic microbe
Year: 2019 PMID: 30740053 PMCID: PMC6355695 DOI: 10.3389/fphar.2019.00022
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Fundamental mechanisms of phagosome maturation. Initiated through (1) Recognition and engulfment of opsonised microbe and expression of phospholipids and phosphoinositide 3-kinase (PI3k), at the extending pseudopodia. (2) Nascent phagosome is formed after actin polymerization facilitates pseudopod closure behind the microbe. This phagosome is characterized by Rab5, phosphatidylinositol 3-phosphate (PI3P) and endosomal early antigen 1 (EEA1) expression. (3) The late phagosome is characterized by Rab7 recruitment; resulting in Rab5 inactivation and PI3P degradation as well as recruitment of lysosome-associated membrane proteins (LAMP) while achieving dynein linkage and centripetal movement for later lysosomal fusion. Rab7 achieves these processes via Rab7-interacting-lysosomal-protein (RILP) and oxysterol-binding protein related-protein 1 (ORP1L). Lysosome fusion initiates the last stage in maturation; (4) Phagolysosome biogenesis, where LAMP expression is increased and lysosomal content is dumped into the phagosome. Rab20 also allows an acidic environment through the action of vacuolar-type H+-ATPase (V-ATPase).
Examples of intracellular microbes and main outcomes of endocytic pathway modulation.
| Organism | Disease state | Type of endocytic modulation | Outcome of endocytic modulation | Egress and dissemination |
|---|---|---|---|---|
| Brucellosis/Malta Fever | Modulation of phagosome maturation | VirB (T4SS) dependent modulation of phagosome, Suppression of macrophage polarization | Cell necrosis/apoptosis (VirB and bacterial dissociation dependent) followed by extracellular dissemination | |
| Legionnaires disease | Prevention of phagosome maturation | Dot/Icm (T4BSS) dependent prevention of phagosome maturation | Pyroptosis, Apoptosis, Cell lysis | |
| Listeriosis | Prevention of phagosome maturation, phagosome rupture | Listeriolysin-O dependent lysis of phagosome or induction of autophagy for replication | Cell-to-cell spread (ActA/LLO-dependent) | |
| Genital/respiratory infections | Subversion of endocytic pathway via inclusion formation | Inc/CT229 dependent inclusion development | Cell lysis, Inclusion extrusion | |
| Tuberculosis | Prevention of phagosome maturation, phagosome rupture | LAM/SapM dependent interference of PI3k and PI3P biogenesis. Inhibition of H+ V-ATPase assembly. ESX-1/EsxA and PDIM dependent phagosome rupture | Cell necrosis/apoptosis | |
| Salmonellosis | Modulation of phagosome maturation | Modulation of phagosome maturation via T3SS effector (SifA, SopB) dependent development of SCV | Pyroptosis | |
| Cryptococcal meningitis | Unknown effectors. Possible pH dependent phagosome damage. Capsular protection. | Unknown effectors. Possible pH modulation through phagosome damage. | Non-lytic expulsion, cell lysis, cell-to-cell spread |
FIGURE 2Visual representation of the proposed system. (A) Simultaneous preparation of the synthetic microbes (1) and autologous macrophages (2) are followed by introduction of the synthetic microbe into phagosome maturation arrested macrophages (3). The complete system can now be administered into circulation for in vivo delivery. (B) Intracellular events for in vitro engulfment of synthetic microbe (3), in vivo maintenance/expulsion (4–7) and final delivery of drug at target site (8–9).